Hematopoietic stem and progenitor cells (HSPC) reside in the bone marrow (BM) niche and serve as a reservoir for mature blood cells throughout life. Aging in the BM is characterized by low-grade chronic inflammation that could contribute to the reduced functionality of aged HSPC. Mesenchymal stromal cells (MSC) in the BM support HSPC self-renewal. However, changes in MSC function with age and the crosstalk between MSC and HSPC remain understudied. Here, we conducted an extensive characterization of senescence features in BM-derived MSC from young and aged healthy donors. Aged MSC displayed an enlarged senescent-like morphology, a delayed clonogenic potential and reduced proliferation ability when compared to younger counterparts. Of note, the observed proliferation delay was associated with increased levels of SA-β-galactosidase (SA-β-Gal) and lipofuscin in aged MSC at early passages and a modest but consistent accumulation of physical DNA damage and DNA damage response (DDR) activation. Consistent with the establishment of a senescence-like state in aged MSC, we detected an increase in pro-inflammatory senescence-associated secretory phenotype (SASP) factors, both at the transcript and protein levels. Conversely, the immunomodulatory properties of aged MSC were significantly reduced. Importantly, exposure of young HSPC to factors secreted by aged MSC induced pro-inflammatory genes in HSPC and impaired HSPC clonogenic potential in a SASP-dependent manner. Altogether, our results reveal that BMderived MSC from aged healthy donors display features of senescence and that, during aging, MSC-associated secretomes contribute to activate an inflammatory transcriptional program in HSPC that may ultimately impair their functionality.
| INTRODUCTION
Hematopoietic stem and progenitor cells (HSPC) can self-renew and differentiate into all blood components thus serving as a reservoir for mature blood cells throughout life. However, as we age, HSPC functionality is impaired with cells displaying a reduced capacity to maintain tissue homeostasis (Geiger, de Haan, & Florian, 2013) .
Indeed, although the number of phenotypically defined HSPC increases with aging, aged HSPC display impaired regenerative capacity when transplanted into host recipients and a differentiation skewing toward the myeloid hematopoietic lineage (Geiger et al., 2013) .
Hematopoietic stem and progenitor cells reside in the BM niche, and their function is supported by a variety of both hematopoietic and nonhematopoietic cell types, such as osteoblasts, adipocytes, endothelial, and mesenchymal stromal cells (MSC) (Morrison & Scadden, 2014) . Among these, BM-derived MSC are multipotent cells of mesodermal origin capable of adhering to culture dishes, proliferate in vitro, and differentiate into different lineages, including osteoblasts, adipocytes, and chondrocytes. Several studies highlighted the key role of MSC in regulating HSPC fate and promoting engraftment of the rare and more primitive hematopoietic stem cells (HSC) (Kfoury & Scadden, 2015) . Even if the molecular mechanisms that regulate HSPC dysfunction in the elderly are thought to be primarily cell-intrinsic, recent insights support the contribution of external cues from the niche to HSPC dysfunction during aging (Adams et al., 2007; Geiger et al., 2013; Mendez-Ferrer et al., 2010) . Indeed, changes in the cellular composition of the HSC niche during aging contribute to hematologic decline and involve decreased bone formation, enhanced adipogenesis, increased BM inflammation, and altered HSPC-MSC crosstalk (Mendelson & Frenette, 2014) . Consistent with this, some studies, mainly conducted in mouse settings, have reported that MSC decrease in number with aging and display a more pronounced differentiation toward the adipogenic lineage at the expenses of bone formation (Liu, Xia, & Li, 2015) . Senescent cells accumulate during aging (Campisi, 2005; Farr et al., 2017) and contribute to tissue dysfunction and impaired tissue regeneration. Senescent cells display an enlarged morphology coupled with a proliferation arrest mediated by the Rb/p16 and p53/p21 pathways. Senescence is also characterized by increased SA-β-Gal activity, persistent DDR activation, and telomeric attrition. Moreover, senescent cells exhibit transcriptional activation of a senescent-associated secretory inflammatory phenotype collectively known as SASP (Coppe et al., 2008) . The robust secretion of SASP chemokines/cytokines triggers an inflammatory response that could reinforce senescence in a cell-autonomous fashion and be transferred to surrounding cells through paracrine mechanisms, to amplify the senescence response. To date, the activation of a senescence program in human aged MSC and the interplay between aged MSC and HSPC remain to be elucidated. In this study, we successfully established human BM-derived MSC from young and elderly healthy donors. We investigated the effects of chronological age on MSC properties and found that MSC derived from aged healthy subjects show senescence-like features comprising an enlarged morphology, reduced proliferation capacity, delayed cell cycle progression, and increased levels of SA-β-Gal and lipofuscin. Importantly, we found that aged MSC activate a SASP-like program that contributes in a non cell autonomous manner to impair young HSPC clonogenicity by mediating an inflammatory state in HSPC.
| RESULTS

| Aged MSC display reduced clonogenic capacity compared to younger counterparts
To identify molecular determinants of MSC aging, we derived MSC from bone marrow (BM) of healthy subjects belonging to three different age groups: pediatric (<18 years) (n = 4), young adults (18-35 years) (n = 6), and aged subjects (≥70) (n = 12) (See Experimental Procedures section for details). Pediatric and young adult subjects were BM donors for hematopoietic stem cell transplantation (HSCT), while BM samples from aged donors were collected from healthy subjects undergoing primary hip replacement. In the efforts to identify features of healthy chronological aging in MSC and to avoid any confounding effect due to underlying age-related pathologies, we excluded from our analysis subjects with compromised immune functions and previous history of cancer or cancer treatments, even if most elderly subjects in our cohort were diagnosed with hypertension. Of note, none of the elderly subjects under study displayed symptoms of overt frailty upon clinical assessment.
We isolated mononuclear cells (MNC) from BM by density gradient centrifugation; after depletion of CD34 + cells purified from MNC by immunomagnetic selection, we plated the remaining CD34 − fraction for MSC ex vivo expansion in culture medium supplemented with 5% platelet lysate, state-of-the-art protocol for derivation of human MSC for clinical use in transplantation settings and regenerative medicine (Avanzini et al., 2009; Ingo et al., 2016) . First, we verified that established MSC from young and aged BM conform to the International Society for Cell & Gene Therapy (ISCT) minimal definition criteria that include plastic adherence and spindle-shape morphology, immunophenotype, and multilineage differentiation potential (Dominici et al., 2006) . We first analyzed MSC samples from the three age groups by flow cytometry and evaluated the expression of established MSC surface markers. We observed that MSC from pediatric, young adults, and aged subjects expressed canonical MSC markers including CD90, CD105, and CD73 and were negative for the expression of hematopoietic/endothelial markers such as CD45, CD34, CD14, CD31, and HLA-DR (representative examples shown in Figure 1a ). We next evaluated the clonogenic potential of MSC by measuring colonies formed unit-fibroblasts (CFU-F), a property of the more primitive enriched MSC subsets (Sacchetti et al., 2007; Tormin et al., 2010) . At the time of MSC derivation, we counted the number of clones generated at 7 and 14 days normalized for the number of MNC seeded. Interestingly, despite some individual donor variability, we did not detect any significant difference in the clonogenic capacity of MSC derived from pediatric and young adult donors (hereafter used as a unified group and defined as "young"). Instead, MSC from aged individuals displayed a significant reduction of CFU-F ability at day 7 compared to younger counterparts that was partially rescued at day 14 (Figure 1b) .
In order to identify intrinsic alterations in MSC phenotype during advanced aging and their impact on hematopoietic stem cell functionality, we randomly selected up to 8 aged MSC samples and consistently analyzed them in comparison with up to 6 MSC samples from the "young" group. To minimize the effect of culture-induced alterations on MSC biology and functionality and better resemble MSC properties in the BM, we focused all our analyses on ex vivo expanded MSC at early passages in culture (between passage P2 and P4).
Given that the CFU-F ability was impaired in aged MSC, we evaluated the expression of two different surface markers that are used to identify primitive MSC, CD146 (melanoma cell adhesion molecule -MCAM) (Sacchetti et al., 2007) , and CD271 (nerve growth factor receptor-NGFR) (Mabuchi et al., 2013 Altogether, these data indicate that MSC were successfully derived from aged BM and displayed an impaired clonogenic potential associated with a significant reduction of mesenchymal primitive cell surface markers and with a mild impairment in the differentiation ability toward the osteogenic lineage.
| An early-senescence state characterizes aged human BM-derived MSC
Having observed a reduced clonogenic capacity of aged MSC compared to younger counterparts, we asked whether aged MSC display reduced proliferation capacity and induction of cell senescence markers even at early passages in culture. First, we noticed that the morphology of aged MSC was more flat and enlarged compared to spindle-shaped young cells, resembling senescent fibroblasts (Figure 2a) . Since fully senescent cells are characterized by a stable cell cycle arrest, we measured the proliferative ability of young and aged MSC. We carried out bromodeoxyuridine (BrdU) incorporation assays to evaluate the percentage of MSC in the active S-phase of the cell cycle and detected a significantly lower proliferation rate of aged MSC compared to young MSC at early passages in culture (Figure 2b, c) , although 50% of aged MSC were still able to enter in Sphase under these conditions. To better quantify cell cycle progression in single human MSC from young and aged donors, we generated a lentiviral bicistronic reporter vector encoding fluorescent ubiquitination-based cell cycle indicator probes (Fucci system). The lentiviral vector expresses mVenus-hGeminin(1/110) fused to mCherry-hCdt1(30/120) by the T2A peptide using an EF1α promoter that generates optimal levels of gene expression in primary cells (Pineda et al., 2016) . These fluorescent reporters allow us to discriminate between three cell cycle phases as G1 by red fluorescence, G1/S by yellow fluorescence, and S/G2/M by green fluorescence.
After a one-hit transduction protocol, we monitored cell cycle transit up to 6 days in live imaging from young and aged MSC. Lentiviral transduction did not alter cell morphology or induced overt cell We next evaluated whether aged MSC had increased amount of oxidative stress. We measured the levels of reactive oxygen species (ROS) and reported a significant increase in ROS levels in aged MSC compared to younger MSC (Supporting information Figure S2b ). The accumulation of cellular ROS was in line with the decreased expression levels of FOXO4 in aged MSC (Supporting information Figure S2c), a factor that has been previously shown to protect from oxidative stress during cellular homeostasis (Klotz et al., 2015) . We also tested whether aged MSC display signs of oxidative DNA damage by measuring oxidation on guanosine residues by immunostaining with an antibody against 8-oxo-dG. Apparently, no increased oxidative DNA damage was detected in aged samples compared to young MSC (Supporting information Figure S2d ). We next evaluated 
| Aged MSC display a pro-inflammatory SASPlike program
Mesenchymal stromal cells exert potent anti-inflammatory and immune-suppressive functions on cells from the adaptive and innate Overall, these findings indicate that aged MSC display reduced immunomodulatory properties and increased levels of pro-inflammatory molecules and suggest that aged stromal cells may contribute to alterations of the BM niche in a non cell-autonomous fashion.
| Aged MSC secretomes activate inflammatory genes in young HSPC
We next Albeit not significant, we also reported a trend toward an increase for IL1α and IL6 mRNA levels in cells grown with CM derived from aged MSC (Supporting information Figure S5d ,e).
We next tested the hypothesis that aged MSC from subjects 
| SASP inhibition in aged MSC rescues clonogenicity in young HSPC
In order to assess the direct effects of SASP inhibition on aged MSC and identify the molecular events that regulate the propagation of inflammation from MSC to HSPC, we employed ex vivo SASP inhibitor treatments on aged MSC. We first performed a 6 days long treatment with corticosterone, a glucocorticoid previously reported to dampen activation of SASP in senescent fibroblasts (Laberge et al., 2012) . We measured the transcript levels of a panel of pro-inflammatory SASP molecules and found a dose-dependent We also showed that the inflammatory program of aged MSC could be transferred in a paracrine fashion to HSPC, and likely contribute to age-associated dysfunction of HSPC and bone marrow microenvironment inflammation. Finally, by employing SASP inhibitors treatment, we provide molecular evidence for the functional role of SASP in mediating HSPC dysfunction upon exposure to aged MSC secretomes.
Mesenchymal stromal cells are a rare and heterogeneous population present at very low frequency in both neonatal and adult tissues and represent only 0.01%-0.001% of nucleated cells in the BM. For this reason, MSC need to be extensively expanded in culture to be studied and/or used for clinical applications (Bernardo, Locatelli, & Fibbe, 2009; Kfoury & Scadden, 2015) . We successfully derived MSC from several aged healthy donors thus indicating that advanced age does not preclude MSC generation and expansion. It is well accepted that MSC undergo replicative senescence after prolonged in vitro culture (Bernardo et al., 2007; Izadpanah et al., 2008; Wagner et al., 2008) , reason for which we confined our molecular and cellular analysis within the first passages in culture. Unexpectedly, we report that, at early passages, aged MSC retain some capacity to actively progress to the S-phase, although reduced compared to younger counterparts and display signs of early senescence rather than stable cell cycle arrest. Given that MSC require a few days to be established ex vivo, it is possible that, if present, the most senescent cells in aged BM may be counter-selected during the first days of in vitro culture possibly due to the loss of their clonogenic capacity. Indeed, in our experiments aged MSC displayed a significantly reduced ability to form clones after plating as compared with young MSC. Another intriguing explanation for the absence of fully senescent MSC in the BM of elderly subjects is the possibility that senescent cells may still be cleared in vivo through the recruitment of immune cells via SASP factors (Lujambio, 2016) .
The multipotent potential of MSC and their differentiation ability have been extensively dissected in mouse and human settings. In F I G U R E 6 SASP inhibitors rescue the clonogenic impairment of young HSPC exposed to CM from aged MSC. aging. Of note, in our cohort, in order to avoid any confounding effect due to underlying age-related diseases, we excluded from the analysis patients with significant co-morbidities and inflammatory conditions, including cancer and immunological defects.
Our findings indicate for the first time that early senescent BMderived MSC activate a robust pro-inflammatory transcriptional program and display reduced immunomodulatory capacity toward cells of the adaptive immune system. As a consequence, aged MSC contribute to create and sustain an inflammatory milieu in the BM niche.
These data indicate that, in concert with a cell-autonomous dysfunction of aged MSC, extrinsic factors may as well alter MSC crosstalks with other BM cellular components. TGF-β pathway has only recently emerged as a key mediator of the senescence associated with aged MSC derived from osteoarthritic bones (Kawamura et al., 2018) .
When measuring the expression levels of TGF-β in our aged MSC, we did not observe any significant increase compared to younger MSC. Instead, the levels of well-established SASP factors, including IL1, IL6, IL8, and MCP1, were higher in aged MSC and actively secreted. In particular, MCP1 was among the most highly expressed SASP factors in aged MSC both at the transcript and protein levels. Consistent with these findings, MCP1 was reported to be epigenetically repressed in umbilical cord blood-derived MSC and activated only when cells reach premature senescence due to prolonged culture conditions (Jin et al., 2016) .
Here, we provide evidence that factors secreted by aged MSC drive an inflammatory transcriptional program in young HSPC and contribute to their clonogenic impairment. Over the past decade, a growing body of evidence revealed that inflammatory stimuli alter HSPC fate and functionality by affecting HSPC proliferation/quiescence status, differentiation potential, or HSPC-niche interactions. In particular, it has been reported that chronic inflammation drives HSPC myeloid skewing and leads to HSPC exhaustion during aging (Essers et al., 2009; Haas et al., 2015; Pietras et al., 2016) . 
| EXPERIMENTAL PROCED URES
| Human samples and cell lines
Mesenchymal stromal cells were isolated from pediatric subjects (<18 years) (n = 4; range 5-15; median 7 years); young adults (18-35 years) (n = 6; range 25-32; median 27 years); and aged subjects (≥70) (n = 12; range 72-89; median 76 years). Pediatric and young subjects donated BM for hematopoietic stem cell transplantation (HSCT) at the San Raffaele Hospital, Milan. Aged MSC were derived from BM samples collected from n = 12 aged subjects who underwent hip replacement surgery at San Raffaele Hospital, Milan, after obtaining written informed consent. For all the samples, the clonogenic capacity at day 7 was tested ( Figure 1b ). As we did not observe any significant difference in the number of clones of MSC derived from pediatric and adult donors, we used these samples as a unifying "young" group and consistently analyzed up to 6 samples for subsequent experiments. In comparison with the "young" group, we randomly selected up to 8 aged samples for molecular and functional analyses on senescence features and consistently analyzed them throughout the manuscript for all the experiments. We excluded from our analyses all subjects with compromised immune functions and previous history of cancer or cancer treatments. We also excluded subjects that were positive to HBV, HCV, and HIV infections. The vast majority of the elderly subjects were diagnosed with hypertension. Frailty in geriatric assessment has only recently been recognized as a medical condition that identifies elderly individuals with unintentional weight loss, muscle weakness, a feeling of fatigue, slow walking speed, low levels of physical activity, chronic inflammation, depression, and social awkwardness. When we evaluated the subjects in our cohort by the Edmonton Frailty Scale (EFS; Perna et al., 2017) , we only found one subject with an "apparently vulnerable" frailty score, who was not included in our molecular and functional studies. All the other subjects scored as "no frail," most likely suggesting that our BM aspirates were collected from healthy aged subjects eligible for primary hip replacement surgery. Only for experiments shown in Figure 5 and Supporting information Figure S5 Table S1 . BJ normal human fibroblasts were purchased from ATCC and grown in DMEM supplemented with 10% FBS (EuroClone), 1% penicillin/streptomycin (Pen/Strep, EuroClone), and 2 mM L-glutamine (L-Glu, EuroClone). . MSC at passage 2-4 (P2-P4) were considered "early passages" MSC, while MSC at passage 10 (P10) were considered "late passages" MSC.
| MSC CFU-F ability and proliferative capacity
Fibroblast colony-forming unit (CFU-F) ability was assessed by examining the cultures at day 7 and 14 after initial seeding; clonogenic efficiency was calculated as number of colonies per 10 6 MNC initially seeded for both young and aged subjects. Population doubling time (PDT) was determined at each passage for each MSC sample by using the formula: PDT= (duration × log(2))/log(Final concentration) -log(Initial concentration) according to http://www.doubling-time.com/com pute.php. Results were expressed as PDT from P3 to P7.
| Flow cytometric analysis
Mesenchymal stromal cells were phenotypically characterized by flow cytometry at early passages to evaluate the presence of canonical MSC surface markers (CD90, CD105, and CD73), primitive MSC markers (CD146, CD271), and the absence of CD45, CD34, CD14, HLA-DR, and CD31 markers. Cells were detached with trypsin and washed with PBS supplemented with 2% FBS. 1 × 10 5 cells were incubated with the proper antibody mix for 10 min at RT in the dark. Unstained cells were used as negative control. All samples were run on BD FACSCanto II cytometer (BD Biosciences). At least events per sample were recorded. Analyses were performed using FlowJo software v9.3.2.
Level of CD146 and CD271 expression was calculated as delta-MFI relative to unstained control (MFI sample-MFI unstained control).
| BrdU incorporation assay
For BrdU incorporation analysis, early passages MSC derived from young and aged donors were seeded at a density of 3 × 10 4 /well GNANI ET AL. 
| MSC differentiation capacity into osteoblasts and adipocytes
The osteogenic and adipogenic differentiation capacity of MSC was 
| Gene expression analysis
Total RNA was extracted using miRNeasy Micro kit (Qiagen) according to the manufacturer's instructions. cDNA synthesis was carried out with iScript cDNA synthesis kit (Bio-Rad) using 30ng of RNA as starting material. 18.75 ng of cDNA was pre-amplified using 1.25 µl of 1 μM pooled primer mix and TaqMan Pre-amp Master Mix (Applied Biosystem) and then used for qPCR after 1:20 dilution.
qPCR was performed using Fast Sybr Green Master Mix (Applied Biosystem). For differentiation analysis, RNA was extracted using RNeasy Micro Kit (Qiagen) according to manufacturer's instructions.
DNase treatment was performed on RNA samples using RNase-Free DNase kit (Qiagen), and cDNA was synthesized from 1 µg total RNA using the high capacity reverse transcription kit (Applied Biosystems).
SYBR Green-based quantitative PCR was performed using Quanti- 
| Alkaline COMET assay
To detect DNA damage in young and aged MSC, we employed alkaline comet assay. Specifically, after trypsinization, 2 × 10 3 MSC were mixed with molten Comet LMAgarose (Trevigen, MD) at a ratio of 1:10 (v/v) and immediately pipetted onto CometSlides (Trevigen, MD) and placed at +4°C. Once solidified, the slides were immersed in prechilled Lysis Solution (Trevigen, MD) for 1 hr at +4°C. Following lysis, slides were immersed in freshly prepared Alkaline Unwinding Solution pH > 13 (300 mM NaOH, 1 mM EDTA) for 1 hr at +4°C and then electrophoresed in alkaline electrophoresis solution pH > 13 (300 mM NaOH, 1 mM EDTA) at 300 mA for 40 min.
Slides were washed twice in ddH2O and fixed in 70% ethanol for 5 min. Comets were stained with SYBR Green for 30 min at RT. All steps were conducted in the dark to prevent additional DNA damage. Comets were analyzed using a Nikon Eclipse E600 microscope and a Nikon-DS-RI2 camera. Up to 75 nuclei for each individual donor were analyzed with CASP software to determine "Olive Tail 
| SASP inhibitor treatments of aged MSC
Late passages aged MSC were treated with 0.5 µM or 2.5 µM corticosterone (Sigma-Aldrich) every other day for 6 days in culture and then collected for gene expression analysis of SASP factors. Ethanol was used as vehicle control. Cells from 3 aged MSC at early passages in culture were treated every other day with 2.5 µM corticosterone for 6 days or vehicle control and then seeded for CM collection. After 48 hr, CM was collected and used to grow young HSPC as described.
Late passages aged MSC were treated for 6 hr with 10 µM or 100 µM of the IKK-2 inhibitor SC-514 (InSolution ™ IKK-2 Inhibitor, Merck) and then collected for gene expression analysis of SASP factors. DMSO was used as vehicle control. Cells from 3 aged donors at early passages in culture were treated with SC-514 100 µM or vehicle control for 6 hr and then seeded for CM collection. After 48 hr, CM was collected and used to grow young HSPC as described.
| Fluorescence in situ hybridization
To analyze telomeres in early passages young and aged MSC, we 
| HSPC colony-forming assays
For the colony-forming unit (CFU) assays, HSPC that were cultured with MSC-derived CM were reseeded onto a 35-mm culture dish (Corning) at a density of 8 × 10 2 cells per dish in triplicate in methylcellulose medium (MethoCult, Stemcell). After 14 days, hematopoietic cell-derived colonies were counted under a light microscope.
The colony types were identified and defined as myeloid (white), erythroid (red), or mixed (gray).
| Statistical analysis
All data are presented as median values or mean ± SD or ±SEM, as indicated. Mann-Whitney test was used for comparisons between two experimental groups. Data were analyzed upon consulting with biostatisticians at CUSSB (University Center for Statistics in Biomedical Sciences) within the San Raffaele Hospital, Milan. Graphs were generated by Prism software v8 (GraphPad Software Inc.). p values <0.05 were considered significant (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
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